Jones Day, Cooley Steer AstraZeneca's $1B Bid For Amolyt
AstraZeneca said Thursday that it has agreed to acquire Amolyt Pharma, a clinical stage biotechnology company, in a deal worth up to $1.05 billion to expand its late-stage rare disease pipeline in...To view the full article, register now.
Already a subscriber? Click here to view full article